Synthaverse S.A. (0RKM.L)

5.30 +5.30 (-) At close: 05:23PM BST

Synthaverse S.A.

Ul. Uniwersytecka 10
Lublin 20-029
Poland
48 81 533 8221
https://www.synthaverse.pl

Sector(s): 
Industry: 
Full-time employees: 239

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Waldemar Sierocki	Secretary of Supervisory Board & Member of Supervisory Board	24k	N/A	N/A
Mr. Mieczyslaw Starkowicz	President of the Management Board & CEO	N/A	N/A	N/A
Radoslaw Wroblewski	Chief Financial Officer	N/A	N/A	N/A
Mr. Jakub Winkler	Chief Organizational & Legal Officer and Member of the Management Board	N/A	N/A	N/A
Ms. Katarzyna Krukowoska	Chief Accountant	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in PLN.

Description

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, Rpmi 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. The company was founded in 1944 and is based in Lublin, Poland.

Corporate governance

Synthaverse S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.